Presentation is loading. Please wait.

Presentation is loading. Please wait.

Design W12 Randomisation * Open-label

Published byAileen Gibson Modified over 5 years ago

Similar presentations

Presentation on theme: "Design W12 Randomisation * Open-label"— Presentation transcript:

1 TRILOGY-3 Study: SOF/VEL/VOX ± RBV in DAA-experienced patients - Phase II
Design W12 Randomisation * Open-label > 18 years Chronic HCV infection Genotype 1 HCV RNA ≥ IU/ml DAA-experienced for ≥ 6 weeks Compensated cirrhosis allowed (around 50%) No HBV or HIV co-infection N = 24 SOF/VEL/VOX SVR12 SOF/VEL/VOX + RBV SVR12 N = 25 * Randomisation was stratified by cirrhosis (yes or no) and NS5A inhibitor experience (yes or no) SOF/VEL/VOX: 400/100/100 mg FDC qd RBV : 1000 or 1200 mg/day, according to body weight Objective SVR12 (HCV RNA < 15 IU/ml), by ITT, with 95% CI TRILOGY-3 Lawitz E. Hepatology 2017; 65:1803-9

2 TRILOGY-3 Study: SOF/VEL/VOX± RBV in DAA-experienced patients - Phase II
Baseline characteristics and outcome SOF/VEL/VOX N = 24 SOF/VEL/VOX + RBV N = 25 Age, years, mean 54 Female, % 33 36 White, % 71 88 HCV RNA, log10 IU/ml, mean 6.2 6.3 IL28B CC, % 8 20 Cirrhosis, % 46 52 Genotype 1a, % NS5A inhibitor experienced, % 42 40 Baseline RASs (1% threshold) 35/48 (73%) ; NS5A only = 15% ; NS3 only = 31% ; multiple class = 27% SVR12 100% 96% (1 relapse) Relapse: 61y, black, male, cirrhosis, IL28B CC, prior treatment with LDV/SOF 24 weeks ; HCV RNA < LLOQ from Day 7 to end of treatment with SOF/VEL/VOX, relapse at W4 post-treatment At baseline of SOF/VEL/VOX At failure NS5A RASs M28V (1.7%), Q30H (3.2%), L31M (> 99%) M28T (> 99%), Q30L (2.4%), Q30R (97.3%), L31M (> 99%) NS3 RASs None V36M (> 99%), Q41R (> 99%), D168G (96.4%), D168S (2.4%) NS5B RASs TRILOGY-3 Lawitz E. Hepatology 2017; 65:1803-9

3 TRILOGY-3 Study: SOF/VEL/VOX ± RBV in DAA-experienced patients - Phase II
Adverse events and laboratory abnormalities % SOF/VEL/VOX SOF/VEL/VOX+ RBV Any adverse event 46 60 Grade 3-4 adverse event 4 (N = 1, grade 3 rash, RBV discontinuation) Serious adverse event 4 Discontinuation for adverse event Adverse events in ≥ 5% of patients Fatigue 36 Anemia 16 Diarrhea 13 Gastroenteritis 8 Bronchitis Nausea Hemoglobin g/dl ; < 8.5 g/dl 24 / 8 TRILOGY-3 Lawitz E. Hepatology 2017; 65:1803-9

4 TRILOGY-3 Study: SOF/VEL/VOX± RBV in DAA-experienced patients - Phase II
Summary SOF/VEL/VOX once daily ± RBV for 12 weeks achieved high SVR12 rate in HCV genotype 1-infected patients with prior DAA experience Addition of RBV did not enhance SVR Baseline RASs did not reduce SVR SVR12 = 13/13 (100%) if no baseline RASs vs 34/35 (97%) if baseline RASs The combination was generally well tolerated Adverse event profile was less good with RBV TRILOGY-3 Lawitz E. Hepatology 2017; 65:1803-9

Download ppt "Design W12 Randomisation * Open-label"

Similar presentations

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,
Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind 18-70 years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:

Egyptian Ancestry  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI SOF 400 mg qd + RBV Randomised 1 : 1 Open-label Egyptian Ancestry Study:
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : 1 18-70 years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥ 10.000.

SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.

SIRIUS Placebo LDV/SOF + placebo Randomisation* 1 : 1 Double-blind SIRIUS Study: LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior.
OBV/PTV/r Placebo Randomisation** 2 : 1 18-75 years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.

OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.

SOF/VEL 400/100 mg qd N = 500 N = 100 W12 Placebo > 18 years Chronic HCV infection Genotype 1, 2, 4, 5 or 6 Naïve or pre-treatment with IFN-based regimen.
SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir.

SOF/VEL 400/100 mg qd N = 250 W24 SOF + RBV W12 * Randomisation was stratified on prior treatment (naïve or experienced) and cirrhosis (yes or no) ** Metavir.
OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.

OBV/PTV/r + DSV Open label Chronic HCV infection Genotype 1 Treatment-naïve HCV RNA > 1,000 IU/ml Chronic kidney disease with eGFR < 30 ml/min/1.73m 2.
No randomisation Open-label 18-70 years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.

No randomisation Open-label years HCV genotype 1 Naïve or null-response to PEG-IFN + RBV HCV RNA > 10,000 IU/ml No cirrhosis No HBV or HIV co-infection.
Roth D. Lancet 2015; Oct 6; 386:1537-45 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR.

Roth D. Lancet 2015; Oct 6; 386: C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, next observation carried backward DCV + SOF + RBV Randomised* 1:1 Open-label ALLY-3+ study: DCV.
SOF + RBV Randomisation* 1 : 1 : 1 Open-label BOSON Study: SOF + RBV + PEG-IFN for genotypes 2 and 3 ≥ 18 years Chronic HCV infection Genotype 2, treatment-

SOF + RBV Randomisation* 1 : 1 : 1 Open-label BOSON Study: SOF + RBV + PEG-IFN for genotypes 2 and 3 ≥ 18 years Chronic HCV infection Genotype 2, treatment-
LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.
SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.

SOF/VEL 400/100 mg qd N = 120 W12 SOF + RBV > 18 years Chronic HCV infection Genotype 2 Naïve or pre-treatment with IFN-based regimen Compensated cirrhosis.
Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148:355-66 COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.

Placebo + PR W24 DCV + PR Placebo + PR Yes Dore GJ. Gastroenterology 2015;148: COMMAND GT2/3 COMMAND GT2/3 Study: daclatasvir + PEG-IFN + RBV for.
 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.

 Objective –SVR 12 (HCV RNA < 25 IU/ml), by ITT OBV/PTV/r + SOF + RBV OBV/PTV/r + SOF Not randomised Open-label QUARTZ-II Study: OBV/PTV/r + SOF for HCV.
No HBV or HIV co-infection

No HBV or HIV co-infection

Similar presentations

Ads by Google